Literature DB >> 7807010

Genetic requirement for Ras in the transformation of fibroblasts and hematopoietic cells by the Bcr-Abl oncogene.

C L Sawyers1, J McLaughlin, O N Witte.   

Abstract

To determine the functional importance of Ras in transformation by Abl oncogenes, we used a genetic approach to measure the effect of impaired Ras activity on the ability of Bcr-Abl or v-Abl to transform cells. Expression of the catalytic domain of the GTPase activating protein for Ras (Gap C terminus) impaired soft agar colony formation by fibroblasts expressing v-Abl or Bcr-Abl by 70-80%. To test Ras function in a model that more closely resembles clinical diseases involving Bcr-Abl, double gene retroviruses expressing Bcr-Abl paired with the Gap C terminus or dominant negative Ras were introduced into naive mouse bone marrow cells. Transformation by Bcr-Abl was completely blocked in both situations. Coexpression of normal c-H-Ras accelerated the transforming activity of Bcr-Abl. These findings show that Ras activation is essential for the leukemogenic activity of Abl oncogenes in two distinct model systems. The results genetically define a connection between the Bcr-Abl cytoplasmic tyrosine kinase and Ras and add to the accumulating evidence that deregulation of Ras is a central event in the genesis of a number of molecularly distinct forms of human myeloid leukemia.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7807010      PMCID: PMC2191855          DOI: 10.1084/jem.181.1.307

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  36 in total

1.  Inhibition of NIH 3T3 cell proliferation by a mutant ras protein with preferential affinity for GDP.

Authors:  L A Feig; G M Cooper
Journal:  Mol Cell Biol       Date:  1988-08       Impact factor: 4.272

2.  Tyrosine kinase activity and transformation potency of bcr-abl oncogene products.

Authors:  T G Lugo; A M Pendergast; A J Muller; O N Witte
Journal:  Science       Date:  1990-03-02       Impact factor: 47.728

3.  Dominant negative MYC blocks transformation by ABL oncogenes.

Authors:  C L Sawyers; W Callahan; O N Witte
Journal:  Cell       Date:  1992-09-18       Impact factor: 41.582

4.  Abl protein-tyrosine kinase selects the Crk adapter as a substrate using SH3-binding sites.

Authors:  R Ren; Z S Ye; D Baltimore
Journal:  Genes Dev       Date:  1994-04-01       Impact factor: 11.361

Review 5.  The bcr-abl gene in chronic myelogenous leukaemia.

Authors:  C L Sawyers
Journal:  Cancer Surv       Date:  1992

6.  SH1 domain autophosphorylation of P210 BCR/ABL is required for transformation but not growth factor independence.

Authors:  A M Pendergast; M L Gishizky; M H Havlik; O N Witte
Journal:  Mol Cell Biol       Date:  1993-03       Impact factor: 4.272

7.  Mutations of the ras protooncogenes in chronic myelogenous leukemia: a high frequency of ras mutations in bcr/abl rearrangement-negative chronic myelogenous leukemia.

Authors:  P C Cogswell; R Morgan; M Dunn; A Neubauer; P Nelson; N K Poland-Johnston; A A Sandberg; E Liu
Journal:  Blood       Date:  1989-12       Impact factor: 22.113

8.  RAS gene mutations in acute and chronic myelocytic leukemias, chronic myeloproliferative disorders, and myelodysplastic syndromes.

Authors:  J W Janssen; A C Steenvoorden; J Lyons; B Anger; J U Böhlke; J L Bos; H Seliger; C R Bartram
Journal:  Proc Natl Acad Sci U S A       Date:  1987-12       Impact factor: 11.205

9.  An actin-binding function contributes to transformation by the Bcr-Abl oncoprotein of Philadelphia chromosome-positive human leukemias.

Authors:  J R McWhirter; J Y Wang
Journal:  EMBO J       Date:  1993-04       Impact factor: 11.598

10.  Coupling between p210bcr-abl and Shc and Grb2 adaptor proteins in hematopoietic cells permits growth factor receptor-independent link to ras activation pathway.

Authors:  T Tauchi; H S Boswell; D Leibowitz; H E Broxmeyer
Journal:  J Exp Med       Date:  1994-01-01       Impact factor: 14.307

View more
  54 in total

1.  BCR/ABL inhibition by an escort/phosphatase fusion protein.

Authors:  Y M Lim; S Wong; G Lau; O N Witte; J Colicelli
Journal:  Proc Natl Acad Sci U S A       Date:  2000-10-24       Impact factor: 11.205

Review 2.  RAS inhibitors in hematologic cancers: biologic considerations and clinical applications.

Authors:  D M Beaupre; R Kurzrock
Journal:  Invest New Drugs       Date:  1999       Impact factor: 3.850

Review 3.  Applying the discovery of the Philadelphia chromosome.

Authors:  Daniel W Sherbenou; Brian J Druker
Journal:  J Clin Invest       Date:  2007-08       Impact factor: 14.808

4.  Dok-1 independently attenuates Ras/mitogen-activated protein kinase and Src/c-myc pathways to inhibit platelet-derived growth factor-induced mitogenesis.

Authors:  Mingming Zhao; Justyna A Janas; Masaru Niki; Pier Paolo Pandolfi; Linda Van Aelst
Journal:  Mol Cell Biol       Date:  2006-04       Impact factor: 4.272

5.  Regulation of myeloproliferation and M2 macrophage programming in mice by Lyn/Hck, SHIP, and Stat5.

Authors:  Wenbin Xiao; Hong Hong; Yuko Kawakami; Clifford A Lowell; Toshiaki Kawakami
Journal:  J Clin Invest       Date:  2008-03       Impact factor: 14.808

6.  Depletion of Pleckstrin homology domain leucine-rich repeat protein phosphatases 1 and 2 by Bcr-Abl promotes chronic myelogenous leukemia cell proliferation through continuous phosphorylation of Akt isoforms.

Authors:  Isao Hirano; Satoki Nakamura; Daisuke Yokota; Takaaki Ono; Kazuyuki Shigeno; Shinya Fujisawa; Kaori Shinjo; Kazunori Ohnishi
Journal:  J Biol Chem       Date:  2009-03-04       Impact factor: 5.157

7.  Mutant forms of growth factor-binding protein-2 reverse BCR-ABL-induced transformation.

Authors:  M L Gishizky; D Cortez; A M Pendergast
Journal:  Proc Natl Acad Sci U S A       Date:  1995-11-21       Impact factor: 11.205

8.  Structural requirements for function of the Crkl adapter protein in fibroblasts and hematopoietic cells.

Authors:  K Senechal; C Heaney; B Druker; C L Sawyers
Journal:  Mol Cell Biol       Date:  1998-09       Impact factor: 4.272

Review 9.  FoxO tumor suppressors and BCR-ABL-induced leukemia: a matter of evasion of apoptosis.

Authors:  Zainab Jagani; Amrik Singh; Roya Khosravi-Far
Journal:  Biochim Biophys Acta       Date:  2007-10-16

10.  Protein tyrosine phosphatase PTP1B suppresses p210 bcr-abl-induced transformation of rat-1 fibroblasts and promotes differentiation of K562 cells.

Authors:  K R LaMontagne; G Hannon; N K Tonks
Journal:  Proc Natl Acad Sci U S A       Date:  1998-11-24       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.